4800 HAMPDEN LANE, BETHESDA, MD
Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026
Investor Presentation
Other Events
Gain Therapeutics, Inc. Files Prospectus Supplement for $35.5M Offering
Reports Financial Results for Third Quarter 2025 and Provides Corporate Update
Corporate Presentation September 2024 Parkinson’s Disease KOL Event Biomarkers, Clinical Endpoints, and the Path to Disease Modification
Changes in Board, Management or Compensation
FY 2025
Q3
Q2
Q1
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Amended Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Free Writing Prospectus
Correspondence
Submission Upload